Envoya develops an AI-powered gene delivery system utilizing polymer-based nanoparticles for targeted genetic material transport. This platform enhances transfection efficiency and yield while minimizing off-target toxicity through optimized peptide guidance. The company provides flexible, non-toxic delivery solutions designed to overcome significant barriers in gene therapy development.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional gene delivery systems often suffer from limitations such as toxicity, immunogenicity, limited payload capacity, and low transfection efficiency, hindering the development of safe and effective gene therapies and biomedical research applications. These challenges can lead to adverse effects, reduced therapeutic efficacy, and difficulties in delivering larger genetic payloads.
Solution
Envoya develops non-lipid polymer-based nanoparticles for gene delivery, offering a safer and more effective alternative to traditional methods. Their nanoparticles demonstrate superior transfection efficiency (80-90% for pDNA) and enhanced payload capacity while minimizing immune responses and liver accumulation. The nanoparticles are made from FDA-approved materials and are non-toxic in murine models, making them suitable for multiple dosing. Envoya also offers customization services, tailoring the nanoparticles to specific use cases and providing formulation, optimization, and encapsulation services to save researchers time and effort.
Target Audience
Envoya's primary customers include researchers in academic institutions, SMB pharma, enterprise pharma, and CRO/CDMOs who require efficient and safe gene delivery systems for gene therapy development and biomedical research.
Features
- Non-lipid polymer-based nanoparticles for enhanced safety and biocompatibility
- High transfection efficiency (80-90% for pDNA) compared to lipid nanoparticles and viral vectors
- Minimal immunogenicity, reducing the risk of adverse immune responses
- Suitable for multiple dosing due to the non-toxic nature of the nanoparticles
- Superior payload capacity, enabling the delivery of larger genetic materials like pDNA
- Customizable nanoparticle design to suit specific payload and target requirements
- AI-driven design refines nanoparticle compositions to maximize target specificity
- Optimized targeting with custom peptides to guide particles to specific cells or tissues